Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

NCT02747732 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

72

Enrollment

OTHER_GOV

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma
Primary Mediastinal (Thymic) Large B-cell Lymphoma
Transformed Indolent Lymphoma
Recurrent Disease
Refractory Cancer

Interventions

DRUG: Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6

Sponsor

Meirav Kedmi MD

Collaborators

[object Object]